Early combination lipid-lowering therapy is associated with greater achievement of goal LDL-C: Insights from the OPTIMIZE PAD-1 trial

Vasc Med. 2025 Jun;30(3):321-323. doi: 10.1177/1358863X241309839. Epub 2025 Jan 27.

Authors

Connie N Hess^{1

2}, Ashley Daffron³, Mark R Nehler^{2

4}, Michael Szarek^{1

2}, Christopher P Cannon⁵, Judith Hsia^{1

2}, Joseph J Saseen³, Marc P Bonaca^{1

2}

Affiliations

¹ Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA.
² CPC Clinical Research, Aurora, CO, USA.
³ University of Colorado School of Pharmacy, Aurora, CO, USA.
⁴ Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
⁵ Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 39868915
DOI: 10.1177/1358863X241309839

No abstract available

Keywords: implementation science; lipids; peripheral artery disease (PAD); statins.

Publication types

Letter